Quest Diagnostics Incorporated Stock News

Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are

Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?

SECAUCUS, N.J. , May 16, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that its Board of Directors has elected Robert (Rob

SECAUCUS, N.J. , May 15, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend

Overall Drug Positivity Holds Steady at Historically High Rates while Marijuana Positivity Continued Upward Climb in the General U.S. Workforce Marijuana Positivity in the General U.S. Workforce Escal

SECAUCUS, N.J. , May 7, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak

Quest Diagnostics' (DGX) pathology laboratories nationwide are set to get a boost with PathAI's AISight digital pathology image management system.

SECAUCUS, N.J. , May 6, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, announced today that Murali Balakumar, a veteran information technol

Investors are optimistic about Quest Diagnostics (DGX) on strong legacy business growth.

Quest Diagnostics' (DGX) latest transaction combines its oncology expertise and scale with PathAI's AI and digital pathology innovations.

Transaction is part of wide-ranging collaboration to combine Quest's oncology expertise and scale with PathAI's AI and digital pathology innovations to speed diagnosis, improve quality and reduce cost

WASHINGTON — Makers of medical tests that have long escaped government oversight will have about four years to show that their new offerings deliver accurate results, under a government rule vigorou

Quest Diagnostics (DGX) continues its strong momentum of base business revenue growth in the first quarter of 2024.

Quest Diagnostics (DGX) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $1.86 per share. This compares to earnings of $2.04 per share a year ago.

Laboratory operator Quest Diagnostic raised its 2024 profit and revenue forecast on Tuesday after beating first-quarter estimates on robust demand for its diagnostic tests.